Home
NewsNewsNexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, has announced a strategic investment in May Health, a medical device company. This partnership aims to advance a pioneering treatment for PCOS-Related Infertility, addressing a significant gap in women's health. Nexpring Health joined a €10 million ($11.7M) financing round alongside other key investors, including Sofinnova Partners, Trill Impact, and Bpifrance.
Polycystic ovary syndrome (PCOS) is a widespread endocrine condition affecting approximately 10–13% of reproductive-aged women worldwide. It stands as a primary cause of female infertility, as the condition often prevents consistent ovulation. For many patients, the struggle to conceive is a defining challenge, leading to a critical need for innovative solutions to manage PCOS-Related Infertility.
May Health’s breakthrough technology, the Anavi™ System, offers a novel approach to this issue. It is designed as a one-time, office-based procedure intended to restore ovulation in women who have not responded to or are unable to use traditional first-line therapies. The system has already reached significant milestones, receiving CE Mark certification in October 2025. Currently, May Health is advancing its pivotal U.S. Investigational Device Exemption (IDE) trial, known as the REBALANCE study, as it seeks FDA marketing authorisation. The REBALANCE trial is a multicentre, randomised controlled study currently enrolling participants at over 15 fertility centres across the United States.
Wil Boren, CEO of Nexpring Health, emphasised that the investment reflects the company’s commitment to redefining fertility care and supporting innovations that change patient outcomes. Boren stated that May Health’s work helps move the entire field forward by expanding clinical options for both professionals and patients. Colby Holtshouse, President and CEO of May Health, added that women have long required more options to support their family-building journeys while managing PCOS-Related Infertility.
Through this collaboration, Nexpring Health continues its mission of placing clinicians and embryologists at the centre of every breakthrough. By backing the Anavi™ System, the company aims to provide reproductive medicine professionals with the tools needed to deliver consistent, confident outcomes for those hoping to start a family
The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.
Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.
La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.
IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.
Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.
Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.
The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.
